Search Results
Your search for Paul B. Chapman, MD matches 6 pages
Showing 1 - 6Reflections on Long-Term Outcomes With BRAF/MEK Inhibition in Advanced Melanoma
For the treatment of BRAF V600-mutated advanced melanoma, we now have three BRAF/MEK inhibitor combinations that are approved by the U.S. Food and Drug Administration: dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib. Although the toxicity profiles for these combinations ...
Conquer Cancer Honors Oncology Professionals With Merit Awards at the 2019 ASCO Annual Meeting
Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2019 ASCO Annual Meeting Merit Awards. These distinguished awards support oncology trainees who were first authors on abstracts selected for presentation at the ASCO Annual Meeting. This year, Conquer Cancer...
A Conversation with Craig B. Thompson, MD
In November 2010, Craig B. Thompson, MD, was named President and CEO of Memorial Sloan-Kettering Cancer Center (MSK) in New York, succeeding Harold Varmus, MD, who is now Director of the NCI. A cancer clinician and researcher, before coming to Memorial Sloan-Kettering Dr. Thompson was Director of...
A Tribute to James F. Holland, MD, in Celebration of His 90th Birthday
Far and away the best prize that life has to offer is the chance to work hard at work worth doing. —Theodore Roosevelt Longevity, in and of itself, is not an accomplishment. Luck and good genes are just human lottery tickets. Most people fortunate enough to live long lives have a productive sweet ...
2015 ASCO Annual Meeting Planning Committees
The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with more than 28,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees, and thank them for their time and ...
Low Incidence of Infusion-Related Reactions Reported With 30-Minute Ipilimumab Infusion
In a single-institution study reported in the Journal of Clinical Oncology, Momtaz et al found that the rate of infusion-related reactions remained acceptably low when ipilimumab (Yervoy) 3 mg/kg was infused over 30 minutes in patients with advanced melanoma. The currently approved dose of...
